1Haider S, Ahmad N, Anaissie E, et al.Future directions in the clinical management of amyloid light-chain amyloidosis. Leuk Lymphoma, 2014,55(10) :2241-2251.
2Merlini G, Bellotti V.Molecular mechanisms of amyloidosis. N Engl J Med,2003,349(6) :583-596.
3Gertz MA. Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment. Am J Hematol, 2014, 89 (12) : 1132-1140.
4Chee CE,Lacy MQ,Dogan A,et al.Pitfalls in the diagnosis of primary amyloidosis. Clin Lymphoma Myeloma Leuk, 2010,10 ( 3 ) : 177-180.
5van Gameren II, Hazenberg BP, Bijzet J, et al. Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practice. Arthritis Rheum, 2006, 54(6) :2015-2021.
6Gertz MA, Lacy MQ, Dispenzieri A, et al. Autologous stem cell transplant for immunoglobulin light chain anayloidosis : a status report Leuk Lymphoma,2010,51(12) :2181-2187.
7Gertz MA, Li CY, Shirahama T, et al. Utility of subcutaneous fat aspiration for the diagnosis of systemic amyloidosis ( immunoglobulin light chain). Arch Intern Med, 1998,148(4) :929-933.
8Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol, 1995,32( 1 ) :45-59.
9Janssen S, Van Rijswijk MH, Meijer S, et al. Systemic amyloidosis : a clinical survey of 144 cases. Neth J Med, 1986,29 (11) :376-385.
10Gertz MA, Comenzo R, Falk RH, et al.Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL) :a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol,2005,79(4) :319-328.
